Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non Operating Income (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Other Non Operating Income for 6 consecutive years, with -$22000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 4.76% to -$22000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$37000.0 through Dec 2025, up 51.95% year-over-year, with the annual reading at -$37000.0 for FY2025, 51.95% up from the prior year.
  • Other Non Operating Income for Q4 2025 was -$22000.0 at 4D Molecular Therapeutics, down from -$21000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $67000.0 in Q1 2025, with the low at -$158000.0 in Q3 2023.
  • Average Other Non Operating Income over 5 years is -$24944.4, with a median of -$16000.0 recorded in 2021.
  • Peak annual rise in Other Non Operating Income hit 770.0% in 2025, while the deepest fall reached 2000.0% in 2025.
  • Over 5 years, Other Non Operating Income stood at -$7000.0 in 2021, then soared by 142.86% to $3000.0 in 2022, then crashed by 466.67% to -$11000.0 in 2023, then plummeted by 90.91% to -$21000.0 in 2024, then dropped by 4.76% to -$22000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$22000.0, -$21000.0, and -$61000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.